Quanterix (QTRX) Stock Overview
A life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
QTRX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Quanterix Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.09 |
| 52 Week High | US$8.77 |
| 52 Week Low | US$4.05 |
| Beta | 1.07 |
| 1 Month Change | -24.44% |
| 3 Month Change | 21.80% |
| 1 Year Change | -22.22% |
| 3 Year Change | -55.15% |
| 5 Year Change | -92.96% |
| Change since IPO | -65.14% |
Recent News & Updates
Recent updates
Market Still Lacking Some Conviction On Quanterix Corporation (NASDAQ:QTRX)
Jan 10
Quanterix: Still Many Questions After An Eventful 2025
Jan 07Market Cool On Quanterix Corporation's (NASDAQ:QTRX) Revenues Pushing Shares 29% Lower
Aug 28Quanterix Corporation (NASDAQ:QTRX) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 10Even With A 33% Surge, Cautious Investors Are Not Rewarding Quanterix Corporation's (NASDAQ:QTRX) Performance Completely
Jun 13Market Cool On Quanterix Corporation's (NASDAQ:QTRX) Revenues Pushing Shares 30% Lower
Apr 08
Simoa ONE Platform Will Revitalize Immunology And Oncology Markets
Strategic product expansion and key acquisitions could significantly enhance market reach and revenue potential in immunology and oncology markets.Quanterix: Why Pursuing A Big Deal For Akoya?
Jan 11Even With A 36% Surge, Cautious Investors Are Not Rewarding Quanterix Corporation's (NASDAQ:QTRX) Performance Completely
Nov 07We're Hopeful That Quanterix (NASDAQ:QTRX) Will Use Its Cash Wisely
Oct 17Quanterix Corporation: Still Struggling To Gain Traction
Aug 26Take Care Before Jumping Onto Quanterix Corporation (NASDAQ:QTRX) Even Though It's 26% Cheaper
Aug 15Positive Sentiment Still Eludes Quanterix Corporation (NASDAQ:QTRX) Following 25% Share Price Slump
Jun 27Quanterix Corporation's (NASDAQ:QTRX) 31% Cheaper Price Remains In Tune With Revenues
Apr 14Quanterix (NASDAQ:QTRX) Is In A Strong Position To Grow Its Business
Apr 05Quanterix Corporation (NASDAQ:QTRX) Yearly Results: Here's What Analysts Are Forecasting For This Year
Mar 03Here's Why We're Not Too Worried About Quanterix's (NASDAQ:QTRX) Cash Burn Situation
Oct 12Shareholder Returns
| QTRX | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -6.3% | -5.2% | -0.07% |
| 1Y | -22.2% | -4.6% | 13.9% |
Return vs Industry: QTRX underperformed the US Life Sciences industry which returned -4.6% over the past year.
Return vs Market: QTRX underperformed the US Market which returned 13.9% over the past year.
Price Volatility
| QTRX volatility | |
|---|---|
| QTRX Average Weekly Movement | 11.5% |
| Life Sciences Industry Average Movement | 7.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: QTRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: QTRX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 471 | Everett Cunningham | www.quanterix.com |
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays.
Quanterix Corporation Fundamentals Summary
| QTRX fundamental statistics | |
|---|---|
| Market cap | US$284.47m |
| Earnings (TTM) | -US$95.66m |
| Revenue (TTM) | US$130.20m |
Is QTRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QTRX income statement (TTM) | |
|---|---|
| Revenue | US$130.20m |
| Cost of Revenue | US$63.11m |
| Gross Profit | US$67.09m |
| Other Expenses | US$162.75m |
| Earnings | -US$95.66m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.05 |
| Gross Margin | 51.53% |
| Net Profit Margin | -73.47% |
| Debt/Equity Ratio | 0% |
How did QTRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/09 04:42 |
| End of Day Share Price | 2026/02/06 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Quanterix Corporation is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sung Ji Nam | BTIG |
| Kyle Mikson | Canaccord Genuity |
| Matthew Sykes | Goldman Sachs |